OncoMed Pharmaceuticals Inc Financing Cash Flow
OncoMed Pharmaceuticals Inc reported Financing Cash Flow of $89.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-07.
Discontinued › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2019-03-07
- OncoMed Pharmaceuticals Inc net cash provided by (used in) financing activities for the quarter ending 2018-12-31 was $0.00, a 100.00% decline year-over-year.
- OncoMed Pharmaceuticals Inc net cash provided by (used in) financing activities for the quarter ending 2018-09-30 was $47.00K, a 89.91% decline year-over-year.
- OncoMed Pharmaceuticals Inc net cash provided by (used in) financing activities for the quarter ending 2017-12-31 was $1.84M.
- OncoMed Pharmaceuticals Inc net cash provided by (used in) financing activities for the quarter ending 2017-09-30 was $466.00K.
- OncoMed Pharmaceuticals Inc net cash provided by (used in) financing activities for fiscal 2018 was $89.00K, a 97.80% decline from fiscal 2017.
- OncoMed Pharmaceuticals Inc net cash provided by (used in) financing activities for fiscal 2017 was $4.04M, a 93.79% decline from fiscal 2016.
- OncoMed Pharmaceuticals Inc net cash provided by (used in) financing activities for fiscal 2016 was $65.15M.
- OncoMed Pharmaceuticals Inc net cash provided by (used in) financing activities for fiscal 2013 was $105.92M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $47.00K derived: sum of 2 quarters · filed 2019-03-07 | $89.00K 10-K · filed 2019-03-07 | |
| 2018-09-30 | $47.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $89.00K 10-Q · filed 2018-11-01 | ||
| 2018-06-30 | $42.00K 10-Q · filed 2018-08-02 | |||
| 2017-12-31 | $1.84M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $2.31M derived: sum of 2 quarters · filed 2019-03-07 | $4.04M 10-K · filed 2019-03-07 | |
| 2017-09-30 | $466.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $2.20M 10-Q · filed 2018-11-01 | ||
| 2017-06-30 | $1.74M 10-Q · filed 2018-08-02 | |||
| 2016-12-31 | $65.15M 10-K · filed 2019-03-07 | |||
| 2013-12-31 | $20.65M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-18 | $105.90M derived: sum of 2 quarters · filed 2014-03-18 | $105.92M 10-K · filed 2014-03-18 | |
| 2013-09-30 | $85.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-13 | $85.27M 10-Q · filed 2013-11-13 | ||
| 2013-06-30 | $17.00K 10-Q · filed 2013-09-03 | |||
| 2012-12-31 | $10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-18 | -$111.00K derived: sum of 2 quarters · filed 2014-03-18 | -$190.00K 10-K · filed 2014-03-18 | |
| 2012-09-30 | -$121.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-13 | -$200.00K 10-Q · filed 2013-11-13 | ||
| 2012-06-30 | -$79.00K 10-Q · filed 2013-09-03 | |||
| 2011-12-31 | -$681.00K 10-K · filed 2014-03-18 |